Premium
Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas
Author(s) -
Wang Kim L.,
Wu TsungTeh,
Choi In Seon,
Wang Huamin,
Resetkova Erika,
Correa Arlene M.,
Hofstetter Wayne L.,
Swisher Stephen G.,
Ajani Jaffer A.,
Rashid Asif,
Albarracin Constance T.
Publication year - 2007
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.22445
Subject(s) - medicine , epidermal growth factor receptor , adenocarcinoma , stage (stratigraphy) , immunohistochemistry , pathology , lymph node , tissue microarray , oncology , esophageal cancer , metastasis , univariate analysis , carcinoma , cancer , multivariate analysis , biology , paleontology
BACKGROUND. The prognosis for patients with esophageal and esophagogastric junction (EGJ) adenocarcinoma remains poor, even after surgical resection. Pathologic assessment of depth of invasion and lymph node status are the primary prognostic factors in these patients. In patients with esophageal squamous cell carcinoma, increased epidermal growth factor receptor (EGFR) expression has been associated with a worse prognosis. It is not known whether EGFR plays a similar role in esophageal and EGJ adenocarcinomas. METHODS. To address this issue, the authors studied tumor specimens from 103 patients with surgically resected esophageal and EGJ adenocarcinomas (9 patients with stage I disease, 23 patients with stage II disease, 57 patients with stage III disease, and 14 patients with stage IV disease). The expression of EGFR was assessed by immunohistochemical analysis of tissue microarrays. Tumors were considered positive for EGFR expression when >5% of tumor cells were stained and negative when ≤5% of tumor cells were stained. RESULTS. EGFR was expressed in 33 of 103 adenocarcinomas (32%) and was correlated with higher pathologic tumor (T) classification ( P = .02), the presence of lymph node metastasis ( P = .01), and higher pathologic tumor, lymph node, metastasis classification ( P = .02). EGFR expression also was correlated with shorter disease‐free and overall survival in univariate analyses ( P = .001 and P = .004, respectively), and there was a trend toward a correlation between EGFR expression and shorter disease‐free survival in multivariate analyses ( P = .07 and P = .08). The results demonstrated that EGFR expression in esophageal adenocarcinomas was correlated with advanced pathologic tumor classification and lymph node metastasis. EGFR expression also was correlated with poor disease‐free and overall survival, but that correlation was not independent of T classification. CONCLUSIONS. The current findings suggested that EGFR expression correlates with poor prognostic factors and may be used to predict patient outcomes. Cancer 2007. © 2007 American Cancer Society.